Completed PHASE2 INTERVENTIONAL 2-arm NCT02324972

Pilot Efficacy and Safety Study of AQX-1125 in Atopic Dermatitis (KINSHIP)

The KINSHIP Trial: A Randomized, Double-Blind, Multicenter, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of AQX-1125 in Subjects With Atopic Dermatitis by Targeting the SHIP1 Pathway

Sponsor: Aquinox Pharmaceuticals (Canada) Inc.

Conditions Atopic Dermatitis

Interventions AQX-1125 Placebo

Updated 8 times since 2017 Last updated: Dec 8, 2017 Started: Dec 31, 2014 Primary completion: Nov 30, 2015 Completion: Dec 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02324972, this PHASE2 trial focuses on Atopic Dermatitis and remains completed. Sponsored by Aquinox Pharmaceuticals (Canada) Inc., it has been updated 8 times since 2014, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Jan 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Nov 2018 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Nov 2018 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Dec 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Aquinox Pharmaceuticals (Canada) Inc.
Innovaderm Research Inc.

Data source: Aquinox Pharmaceuticals (Canada) Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Montreal, Canada